Oxford Nanopore secured CE‑marking under the EU IVDR and UKCA marking for its GridIon Dx sequencer, positioning the platform for clinical deployment in Europe and the UK; the company also named BioMérieux as an early clinical partner to run TB resistance assays on the device. The regulatory nod marks Oxford Nanopore’s first IVD registration in those markets and supports infectious‑disease and clinical testing ambitions. Separately, Pacific Biosciences reported preliminary Q4 revenue growth and announced a collaboration with the n‑Lorem Foundation and EspeRare to apply long‑read whole‑genome sequencing to the design and characterization of individualized antisense oligonucleotide (ASO) therapies. PacBio said HiFi long reads will support ASO feasibility and molecular characterization in the program. Who’s involved: Oxford Nanopore, BioMérieux, Pacific Biosciences, n‑Lorem, EspeRare; announcements made at JP Morgan and via company releases. The moves reflect sequencing vendors’ pivot from pure research tools toward clinical and therapeutic development markets.